Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of LCZ696 in PARADIGM-HF Patients
NCT02226120Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 41
01
Overview
Phase 3, open-label, single-arm trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF), sponsored by Novartis. Primary endpoint: Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths at 30 months. Started Oct 2014; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02226120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02226120.